Marcus Cannon Doing Well, Thriving Despite Lymphoma

Marcus Cannon, the New England Patriots’ fifth-round selection in the 2011 NFL Draft is recovering well from his non-Hodgkin’s lymphoma, ESPN is reporting. The former TCU standout is currently undergoing chemotherapy for his condition, and as per the report, the recovery is “on a positive course.”

"It's looking better and better every time I go in," Cannon said Thursday on ESPN's "First Take." "The actual lump that was seen at the [NFL] combine has totally disappeared."

While he still has a few more treatments left to go and a number of doctors consultations after that, Cannon describes his current condition as “great” and seems to be very enthusiastic about what the future holds for him.

Having experienced what a serious diagnosis like the one he received means first hand, Cannon also said that he and former Boston College linebacker Mark Herzlich have spoken. Herzlich, of course, returned to play football in 2010 after having been diagnosed with Ewing’s sarcoma.

"We had a good conversation," Cannon said. "We talked a little bit and he gave me some pointers. I just asked him questions about when he was losing his hair and asked him how he was getting through it. We shared our stories. It was a friendly talk, like I was talking to another teammate."

A strong-willed individual on and off the field, Cannon is an asset to the Patriots organization and will no doubt be one of the truly great stories to follow whenever the football season ends up kicking off.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap